Rua Bioscience Limited logo

Rua Bioscience continues Australian expansion

Operational Update1 April 2024RUAHealthcare

2
nd

April 2024

FOR PUBLIC RELEASE

Rua Bioscience conƟnues Australian expansion.

TairawhiƟ, New Zealand – Rua Bioscience is conƟnuing to expand its offering in Australia, one of the

largest medicinal cannabis markets in the world.

With company licences and distribuƟon channels established in 2023, Rua successfully launched into

this key market last September with a dried flower product.

It has now extended the range with the introducƟon of full spectrum oil products and liquid

vaporisaƟon cartridges.

“Australia has always been an important focus for us,” said CEO Paul Naske.

“Now that we have a broader range of products available in Australia, we are well posiƟoned to

develop a strong sales presence and build the Rua brand there.”

This push into Australia is supported by Rua’s recent appointment of their first Australian-based Chief

of Sales and MarkeƟng, to drive growth and market share.

“Rua’s strategy is to commercialise our unique geneƟcs on a global scale,” added Mr Naske. “In the

coming months, we’re aiming to launch a range of medicinal cannabis products using our New

Zealand geneƟcs into the Australian market.”


ENDS

The person who authorised this announcement:


Paul Naske

Chief ExecuƟve Officer

paul.naske@ruabio.com

+64 21 445154


For media inquiries, please contact:

Paul Naske - paul.naske@ruabio.com

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.

  • AFT — AFT Pharmaceuticals Limited: AFT reports record revenue and earnings
    2024-05-22

    Australia NEW PRODUCT LAUNCHES FUELLING GROWTH Revenue in Australia grew 15% led by a mixture of organic and new product growth to $108.2 million from $94.1 million in the prior year. Growth came from the OTC channel which was up 24% with the company seeing good demand across…”

  • AFT — AFT Pharmaceuticals Limited: NEW YEAR LETTER TO INVESTORS
    2024-01-08

    AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com It is important to temper growth expectations in these markets. As we have demon…”

  • MEE — Me Today Limited: Me Today half year results and restructure plan
    2024-02-27

    2 Subject to approval from shareholders, the new capital is being raised at 8 cents per share. The raise will be via a partially underwritten non-renounceable rights issue, providing all shareholders the opportunity to participate in the raise should they wish to do so. Li…”